Quarterly report pursuant to Section 13 or 15(d)

Business Combinations - Summary of Fair Value of Purchase Price Consideration (Details)

v3.21.2
Business Combinations - Summary of Fair Value of Purchase Price Consideration (Details) - Pandologic Ltd [Member]
$ in Thousands
Sep. 14, 2021
USD ($)
Business Acquisition [Line Items]  
Cash consideration at closing $ 58,733
Equity consideration at closing 31,500
Contingent earnout 30,000
Total 116,633
Contingent Consideration  
Business Acquisition [Line Items]  
Contingent earnout $ 26,400